Abstract: Herein we report the first example of an isoDGR-drug conjugate (2), designed to releasep aclitaxel selectively within cancerc ells expressing integrin a V b 3 . Conjugate 2 was synthesized by connecting the isoDGR peptidomimetic 5 with paclitaxel via the lysosomally cleavable Val-Ala dipeptide linker.C onjugate 2 displayed al ow nanomolara ffinity for the purified integrin a V b 3 receptor (IC 50 = 11.0 nm). Thet umor targeting ability of conjugate 2 was assessed in vitro in anti-proliferative assays on two isogenicc ancer cell lines characterized by different integrin a V b 3 expression:h uman glioblastoma U87 (a V b 3 +)a nd U87 b 3 -KO (a V b 3 À). The isoDGR-PTX conjugate 2 displayed ar emarkable targeting index (TI = 9.9), especially when compared to the strictly related RGD-PTX conjugate 4 (TI = 2.4).
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Nowadays, the development of molecular devices able to selectively deliver chemotherapeutics at the disease site has gained ac entral positioni nc ancer research. In particular,s uch targetinga gents would allow circumventing the lack of selectivity observed when administering cytotoxic agentst op atients. Due to this main limitation, traditional chemotherapy requires the use of high drug dosages, with consequent severe side effects that vitiate the overall efficacy of the therapy.
[1] A first approachc onsisted in the preparation of antibody-drug conjugates (ADCs), in which the use of monoclonala ntibodies (mAbs) to target specifict umor antigens resulted in ac lear discrimination of cancer cells from healthy tissues. However,t his strategy presents severald rawbacks, especially related to high manufacturing costs, poor pharmacokinetic properties and possible immune-system-induced alteration of drug efficiency. [2] At this stage, small molecule-drug conjugates( SMDCs) arose as an alternative to ADCs:i nt his case, the targeting moietyi sasmall molecule, such as an oligopeptide, ap eptidomimetico ravitamin, capable of interacting selectively with particularp roteins overexpressed by tumor cells. UnlikeA DCs, the use of as mall molecule ascribes improved pharmacokinetic properties to the entire conjugate, which in principle can be synthesized by easier and more affordable synthetic strategies. [2] In the field of SMDCs, integrin a V b 3 represents av ery interesting target to be exploited for the selectived elivery of anticancer agents within the tumor site. As matter of fact, the expression of this transmembrane receptor is increased in avariety of human cancert ypes (e.g.,b reast cancer, glioblastoma, pancreatic tumor,p rostate carcinoma) with respect to healthy tissues. The increased expression of a V b 3 integrin in tumor cells is associated with different pathological features:a ngiogenesis, tumorg rowth, apoptosis resistance, and metastasis. [3] Integrin a V b 3 recognizese ndogenousl igands by the tripeptide arginine-glycine-aspartate [4] (RGD) and also by the related sequence iso-aspartate-glycine-arginine [5, 6] (isoDGR). In 2012, computational andb iochemical studies showed that isoDGRcontaining cyclopeptides act as genuine a V b 3 antagonists, blockingt he ligand bindings ite and inhibitingi ntegrin allosteric activation.
[6a] In contrastt ot he RGD ligands which in some cases may cause adverse paradoxical integrin activation effects, [6a, 7] compounds based on the isoDGRm otif could become an ew generation of integrin-binding drugs free from these drawbacks. For example, isoDGR ligand 1 (Figure 1 ) displays inhibitory effects on the FAK/Akt integrin-activated transduction pathway and on integrin-mediated cell infiltrationp rocesses, qualifying therefore as at rue integrin antagonist.
[8]
Avariety of ligands containing the RGD sequence have been synthesized and reported in the literature so far,w ith some of them showing av ery high affinity for the integrin receptor. [9] [a] S. Zanella,S.Angerani, A. Pina, P. L ópez Rivas, Dr. Moreover,n umerous RGD-drug conjugatesh ave been developed for tumor targeting in the past two decades, [10] [11] [12] while no example of isoDGR-drug conjugate has ever been reported. In fact, compared to the high binding affinity of the RGD ligands for a V b 3 integrin (IC 50 < 15 nm), [9] the isoDGR motif displayed much lower affinity (IC 50 ! 43 nm), [13] with as ingle notable exception (1,IC 50 = 9.2 nm), see Figure 1 .
Herein we report the first example of an isoDGR-drug conjugate (2,F igure 1), based on ligand 1,w hich displays ah igh binding affinity for the purified integrin a V b 3 receptor (IC 50 = 11.0 nm), see Ta ble 1.
Conjugate 2 has been designed in aw ay similar to the corresponding RGD-drug conjugate (4,F igure 1), [10g] which contains the RGD integrinl igand 3.
[14] The isoDGR targeting moietyh as been linked to the cytotoxic agent paclitaxel using the lysosomally cleavable dipeptide Val-Ala:t his sequence showedh igh plasma stability,w hereas it is rapidly cleaved by lysosomal cysteine proteases (such as cathepsins Ba nd D) upon integrin-mediated internalization by endocytosis.
[10g, 15, 16] In order to synthesize conjugate 2,f irst we prepared peptidomimetic 5 (Scheme 1), ad erivative of the isoDGR ligand 1 bearinga na mino functional group suitablef or conjugation. Bifunctional diketopiperazine 6
[10h] was Boc-deprotected and reactedw ith Cbz-Arg(Mtr) to give carboxylic acid 9 upon allyl ester cleavage. Acid 9 was coupled with dipeptide 13,o btained starting from protected aspartic acid 10 (commercially available) and benzyl glycinate 11.T he benzyl (Bn) and carboxybenzyl (Cbz) protecting groups of the resulting compound 14 were selectively removedb yc atalytic hydrogenolysis to afford amino acid 15,w hich was cyclized under high dilution conditions (1.4 mm). Mtr-(4-methoxy-2,3,6-trimethylbenzenesulphonyl)and tert-butyl ester removal on macrolactam 16 afforded the desired isoDGR peptidomimetic 5 after HPLC purification and freeze-drying. The benzylic amine of compound 5 [10g] to give compound 19 (Scheme 2). Treatment of 19 with trifluoroacetic acid in dichloromethane afforded amine 20 which was reacted with carbonate 22 to obtain the final isoDGR-PTXc onjugate 2.
The tumor-targeting ability of conjugate 2 was assessed in vitro against two isogenic cancerc ell lines characterized by different integrin a V b 3 expression. U87 human glioblastoma cells were selected as the integrin a V b 3 -expressing cell line and, at the same time, used to generate the corresponding cloneU 87 b 3 -KO, in which the expression of the gene encoding for the b 3 integrin subunit was deleted using CRISPR-Cas9 gene editing technology. [17] Flow cytometry studies on U87 and U87 b 3 -KO cells confirmed the absence of integrin a V b 3 in the U87 b 3 -KO cell line (Figure 2 ). Clone U87 b 3 -KO is not ap erfect negative control,a st he conjugates can still be actively internalized upon interaction with other integrins, fore xample, a V b 5 .T herefore, the selectivity shown by the conjugates in cell viability experiments using U87 b 3 -KO and U87 cells [IC 50 (a V b 3 À)/IC 50 (a V b 3 +)] should be considered as am inimum (conservative) value. [18] Cells were incubated with increasingd oses of isoDGR-PTX conjugate 2 for 144 h, before measuring the cell viability in culture (Table 2) .
Parallel experiments were performedu nder the same conditions with the RGD-PTXc onjugate 4 ( Figure 1 ) and paclitaxel (PTX, 21) . Paclitaxel itself appeared to be 2.3times more effective on U87 b 3 -KO cells, possibly because the b 3 -integrin-depleted cells divide faster.T aking into account the intrinsic selectivity shown by free paclitaxel, the isoDGR-PTX conjugate 2 displayed ar emarkablet argeting effect( TI = 9.9), especially when compared to the strictly relatedR GD-PTX conjugate 4 (TI = 2.4). Apparently,t he isoDGR-PTX conjugate 2 is recognized more specifically by integrin a V b 3 than the related RGD-PTX conjugate 4 which can be effectively internalized also by other integrins expressed on the cell surface.
Scheme2.Synthesis of isoDGR-drug conjugate 2.Reagents and conditions: a) DIC, NHS, DMF,08CtoRT, overnight;b )5,CH 3 CN/PBS 1:1; pH 7.3-7.6, 0 8Cto RT,overnight;c )TFA/CH 2 Cl 2 1:2, 1h,R T, 55 %o ver three steps;d )4-Nitrophenylchloroformate, pyridine, CH 2 Cl 2 , À50 8Ct oÀ20 8C; 4h,6 9%;e)22, iPr 2 NEt, DMF,08Ct oR T, overnight,5 5%.( PBS = phosphate-buffered saline). Chem.E ur. J.2017, 23,7910-7914 www.chemeurj.org
In conclusion, the first isoDGR-drug conjugate (2)h as been developed for tumor targeting. Compound 2 displayed al ow nanomolar affinity for the purified integrin a V b 3 receptor and an otable targetinga bility when tested on two isogenicc ancer cell lines expressing integrin a V b 3 at differentl evels. Fine tuning of the linker [19] is in progress in order to improve the potencyo ft he conjugate whileretainingt he high selectivity.
